Rocket Pharmaceuticals Announces FDA Alignment on RP-A501 Phase 2 Pivotal Trial

What Happened Rocket Pharmaceuticals, Inc. (RCKT) filed an 8‑K on September 15, 2026 to disclose a press release announcing that it has aligned with the U.S. Food and Drug Administration on continued enrollment, dosing and key design elements of the global pivotal Phase 2 trial of RP‑A501 for Danon disease. The company said the trial will use a recalibrated dose, a 12‑patient pivotal population, and established 12‑month co‑primary endpoints.

Key Details

• Trial: RP‑A501 global pivotal Phase 2 for Danon disease.
• Regulatory alignment date: Announced September 15, 2026.
• Population size: 12‑patient pivotal cohort.
• Endpoints & timing: 12‑month co‑primary endpoints defined.
• Dose: A recalibrated dose has been agreed with the FDA for continued enrollment and dosing.

Why It Matters This disclosure signals that Rocket has secured FDA agreement on core trial parameters (dose, population size and primary endpoints), reducing uncertainty around the study’s design and regulatory expectations. For investors, those clarifications can accelerate enrollment and milestone timing and make upcoming data readouts more meaningful, particularly given the small, well‑defined rare‑disease population. The filing is informational (Regulation FD disclosure) and does not by itself report trial results or financials.